Amundi’s Bionano Genomics BNGO Stock Holding History

Amundi’s Portfolio BNGO Stock Details BNGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-45	Closed	-$59K	–	1908
2022 Q3	$59K	Buy	+45	New	+$59.5K	﹤0.01%	1640

Other funds holding BNGO

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Amundi's BNGO Position: Q4 2022 in Review

Amundi sold out of Bionano Genomics (BNGO) in Q4 2022, closing a stake of 45 shares — an estimated $59K sold.

Amundi first reported a position in BNGO in Q3 2022 and held it in 1 quarter. The position peaked at $59K in Q3 2022. 143 funds tracked by Wall St. Rank hold BNGO as of Q4 2022.

Amundi reported no remaining Bionano Genomics position as of Q4 2022 after selling out during the quarter.
Amundi sold 45 Bionano Genomics shares in Q4 2022, an estimated $59K.
Amundi first reported a position in Bionano Genomics in Q3 2022 and held it in 1 quarter.
Amundi's Bionano Genomics position peaked at $59K in Q3 2022.
143 funds tracked by Wall St. Rank held Bionano Genomics as of Q4 2022.

Based on Amundi's 13F filing for Q4 2022, filed 14 Feb 2023.